Clinical Trial Update: Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels [Phase 3]

View source ↗

Summary

GE Healthcare's Phase 3 trial evaluated PET imaging of brain amyloid and compared imaging results to post-mortem levels; the study has completed and results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: GE Healthcare | Conditions: Brain Fibrillarab Levels | Phase 3 | Status: COMPLETED | Results posted: 2013-12-04